Common Contracts
23 similar Underwriting Agreement contracts by Dermira, Inc., Applied Therapeutics Inc., AquaVenture Holdings LTD, others
BrightSpring Health Services, Inc. [ • ] Shares Common Stock ($0.01 par value) Underwriting AgreementUnderwriting Agreement • January 10th, 2024 • BrightSpring Health Services, Inc. • Services-home health care services • New York
BrightSpring Health Services, Inc., a Delaware corporation (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representative”) are acting as Representative, [ • ] shares of Common Stock, $0.01 par value (“Common Stock”), of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to [ • ] additional shares of Common Stock to cover overallotments, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). Certain capitalized terms used herein are defined in Section 24 hereof.
Verastem, Inc. 7,181,409 Shares of Common Stock Pre-Funded Warrants to Purchase 1,538,591 Shares of Common Stock ($0.0001 par value per share) Underwriting AgreementUnderwriting Agreement • June 21st, 2023 • Verastem, Inc. • Pharmaceutical preparations • New York
Verastem, Inc., a Delaware corporation (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, (i) 7,181,409 shares (the “Underwritten Shares”) of common stock, $0.0001 par value per share (“Common Stock”) of the Company and (ii) pre-funded warrants to purchase an aggregate of 1,538,591 shares of Common Stock at an exercise price equal to $0.001 per share (the “Pre-Funded Warrants” and, together with the Underwritten Shares, the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to 1,308,000 additional shares of Common Stock (the “Option Securities”; the Option Securities, together with the Underwritten Shares, being hereinafter called the “Shares”). The Underwritten Securities and any Option Securities purchased pursuant to this underwriting agreement (this “Agreement”) are herein collectively called the “Se
Applied Therapeutics, Inc. 3,000,000 Shares Common Stock ($0.0001 par value) Underwriting AgreementUnderwriting Agreement • February 17th, 2021 • Applied Therapeutics Inc. • Pharmaceutical preparations • New York
Opendoor Technologies Inc. [●] Shares Common Stock ($0.0001 par value) Underwriting AgreementUnderwriting Agreement • February 2nd, 2021 • Opendoor Technologies Inc. • Real estate agents & managers (for others) • New York
Opendoor Technologies Inc., a Delaware corporation (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, [●] shares of common stock, $0.0001 par value (“Common Stock”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to [●] additional shares of Common Stock (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requires. Certain terms used herein are defined in Section 22 he
Sensei Biotherapeutics, Inc. [•] Shares Common Stock ($0.0001 par value) Underwriting AgreementUnderwriting Agreement • February 1st, 2021 • Sensei Biotherapeutics, Inc. • Pharmaceutical preparations • New York
This press release is not an offer for sale of the securities in the United States or in any other jurisdiction where such offer is prohibited, and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the United States Securities Act of 1933, as amended.
Reata Pharmaceuticals, Inc. 2,000,000 Shares Class A Common Stock ($0.001 par value per share) Underwriting AgreementUnderwriting Agreement • December 3rd, 2020 • Reata Pharmaceuticals Inc • Pharmaceutical preparations • New York
Reata Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule III hereto (the “Underwriters”), for whom Barclays Capital Inc. and Goldman Sachs & Co. LLC (the “Representatives”) are acting as representatives, 2,000,000 shares of Class A common stock, $0.001 par value per share (“Common Stock”), of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to 300,000 additional shares of Common Stock (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule III other than you, the term Representatives as used herein shall mean you, as Underwriter, and the terms Representatives and Underwriters s
Academy Sports and Outdoors, Inc. [●] Shares Common Stock ($0.01 par value) Underwriting AgreementUnderwriting Agreement • September 23rd, 2020 • Academy Sports & Outdoors, Inc. • Retail-miscellaneous shopping goods stores • New York
Academy Sports and Outdoors, Inc., a Delaware corporation (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, [●] shares of Common Stock, $0.01 par value (“Common Stock”), of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to [●] additional shares of Common Stock to cover overallotments, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). Certain capitalized terms used herein are defined in Section 22 hereof.
EX-1.1 2 a2229780zex-1_1.htm EX-1.1 AquaVenture Holdings Limited [ ] Shares Ordinary Shares Underwriting Agreement New York, New York [ ], 2016Underwriting Agreement • May 5th, 2020 • New York
Citigroup Global Markets Inc. Deutsche Bank Securities Inc. RBC Capital Markets, LLC As Representatives of the several Underwriters,
Underwriting AgreementUnderwriting Agreement • January 21st, 2020 • Applied Therapeutics Inc. • Pharmaceutical preparations • New York
Reata Pharmaceuticals, Inc. 2,400,000 Shares Class A Common Stock ($0.001 par value per share) Underwriting AgreementUnderwriting Agreement • November 14th, 2019 • Reata Pharmaceuticals Inc • Pharmaceutical preparations • New York
Reata Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule III hereto (the “Underwriters”), for whom Citigroup Global Markets Inc., Jefferies LLC and SVB Leerink LLC (together, the “Representatives”) are acting as representatives, 2,400,000 shares of Class A common stock, $0.001 par value per share (“Common Stock”), of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to 360,000 additional shares of Common Stock (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule III other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Represen
4,100,000 Ordinary Shares Underwriting AgreementUnderwriting Agreement • July 11th, 2019 • AquaVenture Holdings LTD • Water supply • New York
This letter is being delivered to you in connection with the proposed Underwriting Agreement (the “Underwriting Agreement”), between AquaVenture Holdings Limited, a company incorporated under the laws of the British Virgin Islands (the “Company”), and each of you as representatives of a group of Underwriters named therein, relating to an underwritten public offering of ordinary shares (the “Ordinary Shares”), of the Company (the “Offering”).
ELOXX PHARMACEUTICALS, INC. 3,333,334 Shares Common Stock ($0.01 par value) Underwriting AgreementUnderwriting Agreement • June 21st, 2019 • Eloxx Pharmaceuticals, Inc. • Services-commercial physical & biological research • New York
Eloxx Pharmaceuticals, Inc. a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, the number of shares of common stock, $0.01 par value (“Common Stock”) of the Company set forth in Schedule I hereto (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to the number of additional shares of Common Stock set forth in Schedule I hereto, if any (the “Option Securities;” the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule II other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Un
ELOXX PHARMACEUTICALS, INC. 3,333,334 Shares Common Stock ($0.01 par value) Underwriting AgreementUnderwriting Agreement • June 20th, 2019 • Eloxx Pharmaceuticals, Inc. • Services-commercial physical & biological research • New York
Eloxx Pharmaceuticals, Inc. a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, the number of shares of common stock, $0.01 par value (“Common Stock”) of the Company set forth in Schedule I hereto (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to the number of additional shares of Common Stock set forth in Schedule I hereto, if any (the “Option Securities;” the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule II other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Un
Rosehill Resources Inc. 6,150,000 Shares Class A Common Stock ($0.0001 par value) Underwriting AgreementUnderwriting Agreement • October 1st, 2018 • Rosehill Resources Inc. • Crude petroleum & natural gas • New York
SELLAS Life Sciences Group, Inc. Shares Common Stock ($0.0001 par value per share) Underwriting AgreementUnderwriting Agreement • June 26th, 2018 • SELLAS Life Sciences Group, Inc. • Pharmaceutical preparations • New York
SELLAS Life Sciences Group, Inc., a corporation organized under the laws of Delaware (including any predecessor entities, the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, [ ] shares of common stock, $0.0001 par value per share (“Common Stock”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to [ ] additional shares of Common Stock to cover over-allotments, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall m
Bicapital Corporation Shares Common Stock Underwriting AgreementUnderwriting Agreement • July 11th, 2017 • Bicapital Corp • Commercial banks, nec • New York
Bicapital Corporation, a corporation organized under the laws of the Republic of Panama (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, shares of common stock (“Common Stock”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to additional shares of Common Stock to cover over-allotments, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). Certain terms used herein are defined in Section 24 hereof.
AquaVenture Holdings Limited [ ] Shares Ordinary Shares Underwriting AgreementUnderwriting Agreement • September 23rd, 2016 • AquaVenture Holdings LTD • Water supply • New York
Citigroup Global Markets Inc. Deutsche Bank Securities Inc. RBC Capital Markets, LLC As Representatives of the several Underwriters,
Lantheus Holdings, Inc. 5,200,000 Shares Common Stock ($0.01 par value) Underwriting AgreementUnderwriting Agreement • September 13th, 2016 • Lantheus Holdings, Inc. • In vitro & in vivo diagnostic substances • New York
Lantheus Holdings, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof, and to the extent there is only a single underwriter, the term “Underwriters” shall be deemed to refer to the single Underwriter, mutatis mutandis), 5,200,000 shares of common stock, $0.01 par value (“Common Stock”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Securities”). Any reference herein to the Registration Statement, the Base Prospectus, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include the documents incorporated by reference therein pursuant to Item 12 of Form S-3 which were filed under the Exchange Act on or before the Effective Date of the Registration Statement or the issue date of the Base Pr
Flexion Therapeutics, Inc. 5,500,000 Shares Common Stock ($0.001 par value) Underwriting AgreementUnderwriting Agreement • June 8th, 2016 • Flexion Therapeutics Inc • Pharmaceutical preparations • New York
Dermira, Inc. 4,500,000 Shares Common Stock ($0.001 par value) Underwriting AgreementUnderwriting Agreement • June 8th, 2016 • Dermira, Inc. • Pharmaceutical preparations • New York
Dermira, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, the number of shares of common stock, $0.001 par value (“Common Stock”) of the Company set forth on Schedule I hereto (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to the number of additional shares of Common Stock set forth on Schedule I hereto (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule II other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mea
Bicapital Corporation Shares Common Stock Underwriting AgreementUnderwriting Agreement • August 28th, 2015 • Bicapital Corp • Commercial banks, nec • New York
Bicapital Corporation, a corporation organized under the laws of the Republic of Panama (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, shares of common stock (“Common Stock”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to additional shares of Common Stock to cover over-allotments, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). Certain terms used herein are defined in Section 24 hereof.
Common Stock ($0.001 par value) Underwriting AgreementUnderwriting Agreement • August 4th, 2015 • Dermira, Inc. • Pharmaceutical preparations • New York
Dermira, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, [·] shares of common stock, $0.001 par value (“Common Stock”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to [·] additional shares of Common Stock (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requires. Certain terms used herein a
Dermira, Inc. Shares(1) Common Stock ($0.001 par value) Underwriting AgreementUnderwriting Agreement • September 19th, 2014 • Dermira, Inc. • Pharmaceutical preparations • New York
Dermira, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, shares of common stock, $0.001 par value (“Common Stock”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to additional shares of Common Stock to cover over-allotments, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requires. Ce
